deltatrials
Completed PHASE4 NCT01098487

A Longitudinal 2-year Bone Marrow Study of Eltrombopag in Previously Treated Adults, With Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP)

A Longitudinal 2-year Bone Marrow Study of Eltrombopag Olamine (SB-497115-GR) in Previously Treated Adults, With Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP)

Sponsor: GlaxoSmithKline

Conditions Purpura, Thrombocytopaenic, Idiopathic
Interventions Eltrombopag olamine
Updated 7 times since 2017 Last updated: Feb 26, 2015 Started: May 31, 2010 Primary completion: May 31, 2014 Completion: May 31, 2014

A PHASE4 clinical study on Purpura, Thrombocytopaenic, Idiopathic, this trial is completed. The trial is conducted by GlaxoSmithKline and has accumulated 7 data snapshots since 2010. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Change History

7 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE4

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE4

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE4

  4. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE4

  5. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE4

▶ Show 2 earlier versions

  1. Feb 2017 — Jun 2018 [monthly]

    Completed PHASE4

  2. Jan 2017 — Feb 2017 [monthly]

    Completed PHASE4

    First recorded

May 2010

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • GlaxoSmithKline
Data source: GlaxoSmithKline

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Berlin, Germany, Bologna, Italy, Caen, France, Créteil, France, Debrecen, Hungary, Düsseldorf, Germany, Essen, Germany, Győr, Hungary, Hradec Králové, Czechia, Karachi, Pakistan and 20 more location s